Cited by 1,625COVID-19 Clinical Research StudiesRespiratory Support and MechanismsSARS-CoV-2 and COVID-19 Research

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Open access

Geleris, Joshua, Sun, Yifei, Platt, Jonathan, Zucker, Jason, Baldwin, Matthew, Hripcsak, George, Labella, Angelena, Manson, Daniel K., Kubin, Christine, Barr, R. Graham, Sobieszczyk, Magdalena E., Schluger, Neil W.·2020·New England Journal of Medicine

DOI 10.1056/nejmoa2012410PMC PMC7224609

Open this paper in CoChat — free account

Abstract

BACKGROUND: Hydroxychloroquine has been widely administered to patients with Covid-19 without robust evidence supporting its use. METHODS: We examined the association between hydroxychloroquine use and intubation or death at a large medical center in New York City. Data were obtained regarding consecutive patients hospitalized with Covid-19, excluding those who were intubated, died, or discharged within 24 hours after presentation to the emergency department (study baseline). The primary end point was a composite of intubation or death in a time-to-event analysis. We compared outcomes in patients who received hydroxychloroquine with those in patients who did not, using a multivariable Cox model with inverse probability weighting according to the propensity score. RESULTS: Of 1446 consecutive patients, 70 patients were intubated, died, or discharged within 24 hours after presentation and were excluded from the analysis. Of the remaining 1376 patients, during a median follow-up of 22.5 days, 811 (58.9%) received hydroxychloroquine (600 mg twice on day 1, then 400 mg daily for a median of 5 days); 45.8% of the patients were treated within 24 hours after presentation to the emergency department, and 85.9% within 48 hours. Hydroxychloroquine-treated patients were more severely ill at baseline than those who did not receive hydroxychloroquine (median ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen, 223 vs. 360). Overall, 346 patients (25.1%) had a primary end-point event (180 patients were intubated, of whom 66 subsequently died, and 166 died without intubation). In the main analysis, there was no significant association between hydroxychloroquine use and intubation or death (hazard ratio, 1.04, 95% confidence interval, 0.82 to 1.32). Results were similar in multiple sensitivity analyses. CONCLUSIONS: In this observational study involving patients with Covid-19 who had been admitted to the hospital, hydroxychloroquine administration was not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death. Randomized, controlled trials of hydroxychloroquine in patients with Covid-19 are needed. (Funded by the National Institutes of Health.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2012410

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Gautret, P., Lagier, J., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Esteves-Vieira, V., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288
Retracted
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L. Y., Dong, E., Song, C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa237 · Cited by 2,696
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
Devaux, C. A., Rolain, J., Colson, P., & Raoult, D. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105938 · Cited by 1,122
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial
Borba, M. G. S., Val, F. F. A., Sampaio, V. S., Alexandre, M. A. A., Melo, G. C., Brito, M., Mourão, M. P. G., Brito-Sousa, J. D., Baía-da-Silva, D., Guerra, M. V. F., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.8857 · Cited by 1,038
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trialPreprint
Chen, Z., Hu, J., Zhang, Z., Jiang, S., Han, S., Yan, D., Zhuang, R., Hu, B., & Zhang, Z. (2020) · medRxiv · doi:10.1101/2020.03.22.20040758 · Cited by 861
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
Chen, J., Liu, D., Liu, L., Liu, P., Xu, Q., Xia, L., Ling, Y., Huang, D. F., Song, S., Zhang, D., et al. (2020) · PubMed Central · doi:10.3785/j.issn.1008-9292.2020.03.03 · Cited by 662
Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection
Fantini, J., Scala, C. D., Chahinian, H., & Yahi, N. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105960 · Cited by 566
Mechanism of action of hydroxychloroquine as an antirheumatic drug
Fox, R. I. (1993) · Seminars in Arthritis and Rheumatism · doi:10.1016/s0049-0172(10)80012-5 · Cited by 430
Design and Synthesis of Hydroxyferroquine Derivatives with Antimalarial and Antiviral Activities
Biot, C., Daher, W., Leleu‐Chavain, N., Fandeur, T., Khalife, J., Dive, D., & Clercq, E. D. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0601856 · Cited by 318

Flagged first, then by citations

Show all 17 references

Sorted by citations

Items 501–600 of 1,000

Insights into SARS-CoV-2 evolution, potential antivirals, and vaccines
Abdel-Moneim, A. S., Abdelwhab, E. M., & Memish, Z. A. (2021) · Virology · doi:10.1016/j.virol.2021.02.007 · Cited by 27
Methodological evaluation of bias in observational coronavirus disease 2019 studies on drug effectiveness
Martinuka, O., von Cube, M., & Wolkewitz, M. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.03.003 · Cited by 27
SARS-CoV-2 cell entry and targeted antiviral development
Chen, Z., Du, R., Achi, J. G., Rong, L., & Cui, Q. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.007 · Cited by 27
Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial
Grau-Pujol, B., Camprubí-Ferrer, D., Martí-Soler, H., Fernández-Pardos, M., Carreras‐Abad, C., Andrés, M. V., Ferrer, E., Muelas‐Fernandez, M., Jullien, S., Barilaro, G., et al. (2021) · Trials · doi:10.1186/s13063-021-05758-9 · Cited by 27
Update Alert 3: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19
Hernández, A. V., Roman, Y. M., Pasupuleti, V., Barboza, J. J., & White, C. M. (2020) · Annals of Internal Medicine · doi:10.7326/l20-1257 · Cited by 27
Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir
Rahmani, H. R., Davoudi-Monfared, E., Nourian, A., Nabiee, M., Sadeghi, S., Khalili, H., Abbasian, L., Ghiasvand, F., Seifi, A., Hasannezhad, M., et al. (2020) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-020-00369-2 · Cited by 26
COVID-19: Physiopathology and Targets for Therapeutic Intervention
de Almeida, J. O., de Oliveira, V. R. T., Avelar, J. L. D. S., Moita, B. S., & Lima, L. M. (2020) · Revista Virtual de Química · doi:10.21577/1984-6835.20200115 · Cited by 26
Chloroquine and hydroxychloroquine for COVID‐19: Perspectives on their failure in repurposing
Shah, R. R. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13267 · Cited by 26
Recent Advances in Pathophysiology, Drug Development and Future Perspectives of SARS-CoV-2
Singh, D. D., Han, I., Choi, E. H., & Yadav, D. K. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.580202 · Cited by 26
Interferon β-1a (IFNβ-1a) in COVID-19 patients (INTERCOP): study protocol for a randomized controlled trial
Bosi, E., Bosi, C., Rovere, P. Q., Mancini, N., Calori, G., Ruggeri, A., Canzonieri, C., Callegaro, L., Clementi, M., COBELLI, F. D., et al. (2020) · Trials · doi:10.1186/s13063-020-04864-4 · Cited by 26
Clinical features of 47 patients infected with COVID-19 admitted to a Regional Reference Center
Olivares, F., Muñoz, D. L., Fíca, A., Delama, I., Alvarez, I., Maritza Navarrete, C., Blackburn, E., Garrido, P., Wenger, R., & Grandjean, J. (2020) · Revista médica de Chile · doi:10.4067/s0034-98872020001101577 · Cited by 26
Revised Korean Society of Infectious Diseases/National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19
Kim, S. B., Ryoo, S., Huh, K., Joo, E., Kim, Y. J., Choi, W. S., Kim, Y., Yoon, Y. K., Heo, J. Y., Seo, Y. B., et al. (2021) · Infection and Chemotherapy · doi:10.3947/ic.2021.0303 · Cited by 26
Sepsis of Patients Infected by SARS-CoV-2: Real-World Experience From the International HOPE-COVID-19-Registry and Validation of HOPE Sepsis Score
Abumayyaleh, M., Nuñez-Gil, I. J., El‐Battrawy, I., Estrada, V., Becerra‐Muñoz, V. M., Uribarri, A., Fernández‐Rozas, I., Feltes, G. I., Arroyo‐Espliguero, R., Trabattoni, D., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.728102 · Cited by 26
In silico analysis of SARS-CoV-2 proteins as targets for clinically available drugs
Chan, W. K. B., Olson, K. M., Wotring, J. W., Sexton, J. Z., Carlson, H. A., & Traynor, J. R. (2022) · Scientific Reports · doi:10.1038/s41598-022-08320-y · Cited by 26
COVID-19: Pharmacology and kinetics of viral clearance
Farina, N., Ramirez, G. A., LORENZO, R. D., di Filippo, L., Conte, C., Ciceri, F., Manfredi, A. A., & Rovere, P. Q. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105114 · Cited by 26
Side Effects of Chloroquine and Hydroxychloroquine on Skeletal Muscle: a Narrative Review
Carvalho, A. A. D. S. (2020) · Current Pharmacology Reports · doi:10.1007/s40495-020-00243-4 · Cited by 26
The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis
Mega, T. A., Mulugeta, T., Bosho, D. D., Kumela, K., & Negera, G. Z. (2020) · Canadian Respiratory Journal · doi:10.1155/2020/4312519 · Cited by 25
Health and Economy in COVID-19 Era: A Plan for Reconstituting Long-Term Economic Security
Allen, M. B., & Mirsaeidi, M. S. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.00235 · Cited by 25
COVID-19 in Kidney Transplantation: Epidemiology, Management Considerations, and the Impact on Kidney Transplant Practice
Kataria, A., Yakubu, I., Winstead, R. J., Gowda, M., & Gupta, G. (2020) · Transplantation Direct · doi:10.1097/txd.0000000000001031 · Cited by 25
Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS‐CoV‐2 infection: A retrospective cohort study
Giacomelli, A., Pagani, G., Ridolfo, A. L., Oreni, L. M., Conti, F., Pezzati, L., Bradanini, L., Casalini, G., Bassoli, C. R., Morena, V., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26407 · Cited by 25
Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients
Karolyi, M., Pawelka, E., Mader, T., Omid, S., Kelani, H., Ely, S. J., Jilma, B., Baumgartner, S., Laferl, H., Ott, C., et al. (2020) · Wiener klinische Wochenschrift · doi:10.1007/s00508-020-01720-y · Cited by 25
Observational study of azithromycin in hospitalized patients with COVID-19
Rodríguez‐Molinero, A., Pérez‐López, C., Gálvez‐Barrón, C., Miñarro, A., Macho, O., López, G. F., Robles, M. T., Dapena, M. D., Martínez, S., Rodríguez, E., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238681 · Cited by 25
COVID-19 after hematopoietic stem cell transplantation: report of two children
Zamperlini–Netto, G., Fernandes, J. F., Garcia, J. L., Ribeiro, A. A. F., Camargo, L. F. A., Terra, C. M., & Hamerschlak, N. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01041-8 · Cited by 25
Probiotics and Coronavirus disease 2019: think about the link
Angurana, S. K., & Bansal, A. (2020) · British Journal Of Nutrition · doi:10.1017/s000711452000361x · Cited by 25
The importance of overweight in COVID-19
Rao, X., Wu, C., Wang, S., Tong, S., Wang, G., Wu, G., & Zhou, R. (2020) · Medicine · doi:10.1097/md.0000000000022766 · Cited by 25
Systemic manifestations of COVID-19
Mahajan, R. K., Paul, G., Mahajan, R., Gautam, P., & Paul, B. S. (2020) · Journal of Anaesthesiology Clinical Pharmacology · doi:10.4103/joacp.joacp_359_20 · Cited by 25
Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study
Jung, S., Kim, M.-S., Kim, M., Choi, S., Chung, J.-W., & Choi, S. T. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.12.003 · Cited by 25
Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy
Krueger, J., Santinon, F., Kazanova, A., Issa, M. E., Larrivée, B., Kremer, R. B., Milhalcioiu, C., & Rudd, C. E. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251731 · Cited by 25
Inflammatory risk stratification individualizes anti-inflammatory pharmacotherapy for acute type A aortic dissection
Liu, H., Li, H., Han, L., Zhang, Y., Wu, Y. X., Liang, H., Yang, J., Zhong, J., Wang, Y., Wu, D., et al. (2023) · The Innovation · doi:10.1016/j.xinn.2023.100448 · Cited by 25
Anti-Scientific Americans
Motta, M. (2024) · doi:10.1093/9780197788844.001.0001 · Cited by 26
HRS/EHRA/APHRS/LAHRS/ACC/AHA worldwide practice update for telehealth and arrhythmia monitoring during and after a pandemic
Varma, N., Marrouche, N. F., Aguinaga, L., Albert, C. M., Arbelo, E., Choi, J., Chung, M. K., Conte, G., Dagher, L., Epstein, L. M., et al. (2020) · Heart Rhythm · doi:10.1016/j.hrthm.2020.06.010 · Cited by 25
Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020
Richez, C., Flipo, R., Berenbaum, F., Cantagrel, A. G., Claudepierre, P., Debiais, F., Dieudé, P., Goupille, P., Roux, C., Schaeverbeke, T., et al. (2020) · Joint Bone Spine · doi:10.1016/j.jbspin.2020.05.006 · Cited by 24
Effectiveness of a On-site Medicalization Program for Nursing Homes With COVID-19 Outbreaks
Bernabeu‐Wittel, M., Ternero-Vega, J. E., Nieto‐Martín, M. D., Moreno-Gaviño, L., Guzmán, C. C., Delgado, J., Rincón‐Gómez, M., Díaz-Jiménez, P., Giménez, L., Lomas-Cabezas, J. M., et al. (2020) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaa192 · Cited by 24
Double-Barreled CRISPR Technology as a Novel Treatment Strategy For COVID-19
Nalawansha, D. A., & Samarasinghe, K. T. G. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00071 · Cited by 24
Crosstalk Between Coronavirus Disease 2019 and Cardiovascular Disease and Its Treatment
Ye, Q., Lu, D., Shang, S., Fu, J., Gong, F., Shu, Q., & Mao, J. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12960 · Cited by 24
Preprints During the COVID‐19 Pandemic: Public Health Emergencies and Medical Literature
Guterman, E. L., & Braunstein, L. Z. (2020) · Journal of Hospital Medicine · doi:10.12788/jhm.3491 · Cited by 24
Systematic review and meta-analysis of the effectiveness and safety of hydroxychloroquine in treating COVID-19 patients
Yang, T.-H., Chou, C., Yang, Y., Chien, C., Yarmishyn, A. A., Yang, T.-Y., Liu, C.-H., Chang, K.-J., Yang, Y., & Chang, Y. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000425 · Cited by 24
Access to data from clinical trials in the COVID-19 crisis: open, flexible, and time-sensitive
Ewers, M., Ioannidis, J. P. A., & Plesnila, N. (2020) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2020.10.008 · Cited by 24
Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies—need for data validation of the completed trials and to improve ongoing and future randomised trial designs
Emani, V. R., Goswami, S., Nandanoor, D., Emani, S. R., Reddy, N. K., & Reddy, R. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106222 · Cited by 24
Drug repurposing: new strategies for addressing COVID-19 outbreak
Shende, P. K., Khanolkar, B., & Gaud, R. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1851195 · Cited by 24
Management of Pediatric Kidney Transplant Patients During the COVID-19 Pandemic: Guidance From the Canadian Society of Transplantation Pediatric Group
Teoh, C. W., Gaudreault‐Tremblay, M., Blydt‐Hansen, T. D., Goldberg, A. M., Arora, S., Feber, J., Langlois, V., Ruhl, M., Phan, V., Morgan, C., et al. (2020) · Canadian Journal of Kidney Health and Disease · doi:10.1177/2054358120967845 · Cited by 24
COVID-19
Ashraf, O., Virani, A., & Cheema, T. J. (2020) · Critical Care Nursing Quarterly · doi:10.1097/cnq.0000000000000346 · Cited by 24
Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: A pilot observational study
Söğüt, Ö., Can, M. M., Güven, R., Kaplan, O., Ergenç, H., Ümit, T. B., Demir, O., Kaya, M., Akdemir, T., & Çakmak, S. (2020) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2020.12.014 · Cited by 24
Beneficial Effects of Intermediate Dosage of Anticoagulation Treatment on the Prognosis of Hospitalized COVID-19 Patients: The ETHRA Study
Poulakou, G., Dimakakos, E. P., Κόλλιας, Α., Kyriakoulis, K. G., Rapti, V., Trontzas, I. P., Thanos, C., Abdel‐Rasoul, M., VANTANA, T., Leontis, K., et al. (2021) · In Vivo · doi:10.21873/invivo.12305 · Cited by 24
Synthesis of novel calcium channel blockers with ACE2 inhibition and dual antihypertensive/anti-inflammatory effects: A possible therapeutic tool for COVID-19
Mahgoub, S., El-Sayed, M.-I. K., Shehry, M. F. E., Awad, S. M., Mansour, Y. E., & Fatahala, S. S. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105272 · Cited by 24
Discovery of potential anti-SARS-CoV-2 drugs based on large-scale screening in vitro and effect evaluation in vivo
Peng, H., Ding, C., Jiang, L., Tang, W., Liu, Y., Zhao, L., Yi, Z., Ren, H., Li, C. V., He, Y., et al. (2021) · Science China Life Sciences · doi:10.1007/s11427-021-2031-7 · Cited by 24
Lived experiences of frontline healthcare providers offering maternal and newborn services amidst the novel corona virus disease 19 pandemic in Uganda: A qualitative study
Kayiga, H., Genevive, D. A., Amuge, P. M., Ssemata, A. S., Nanzira, R. S., & Nakimuli, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259835 · Cited by 24
Mapping Scientific Productivity Trends and Hotspots in Remdesivir Research Publications: A Bibliometric Study from 2016 to 2021
Ogunsakin, R. E., Ebenezer, O., Jordaan, M. A., Shapi, M., & Ginindza, T. G. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19148845 · Cited by 25
The failure of drug repurposing for COVID-19 as an effect of excessive hypothesis testing and weak mechanistic evidence
Maziarz, M., & Stencel, A. (2022) · History & Philosophy of the Life Sciences · doi:10.1007/s40656-022-00532-9 · Cited by 24
Successful Treatment of Covid-19 Associated Cytokine Release Syndrome with Colchicine. A Case Report and Review of Literature
Mansouri, N., Marjani, M., Tabarsi, P., von Garnier, C., & Mansouri, D. (2020) · Immunological Investigations · doi:10.1080/08820139.2020.1789655 · Cited by 24
The Potential Therapeutic Role of Proton Pump Inhibitors in COVID-19: Hypotheses Based on Existing Evidences
Ray, A., Sharma, S., & Sadasivam, B. (2020) · Drug Research · doi:10.1055/a-1236-3041 · Cited by 24
Impact of hydroxychloroquine on the gestational outcomes of pregnant women with immune system problems that necessitate the use of the drug
Beksaç, M. S., & Dönmez, H. G. (2020) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.14561 · Cited by 24
Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs
Vernaz, N., Agoritsas, T., Calmy, A., Gayet‐Ageron, A., Gold, G., Perrier, A., Picard, F., Prendki, V., Reny, J., Samer, C. F., et al. (2020) · Swiss Medical Weekly · doi:10.4414/smw.2020.20446 · Cited by 24
Hydroxychloroquine and mortality in COVID-19 patients: a systematic review and a meta-analysis of observational studies and randomized controlled trials
Castelnuovo, A. F. D., Costanzo, S., Cassone, A., Cauda, R., de Gaetano, G., & Iacoviello, L. (2021) · Pathogens and Global Health · doi:10.1080/20477724.2021.1936818 · Cited by 24
Drug repurposing clinical trials in the search for life-saving COVID-19 therapies; research targets and methodological and ethical issues
Paumgartten, F. J. R., Delgado, I. F., Pitta, L. D. R., & de Oliveira, A. C. A. X. (2020) · Vigilância Sanitária em Debate · doi:10.22239/2317-269x.01596 · Cited by 23
Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2
Kohan, H. G., & Jamali, F. (2020) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps31346 · Cited by 23
Tocilizumab use in Kidney Transplant Patients with COVID‐19
Trujillo, H., Caravaca‐Fontán, F., Sevillano, Á., Gutiérrez, E., Fernández‐Ruiz, M., López‐Medrano, F., Hernández, A. M. G., Aguado, J. M., Praga, M., & Andrés, A. (2020) · Clinical Transplantation · doi:10.1111/ctr.14072 · Cited by 23
Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin
Fatima, U., Rizvi, S. S. A., Fatima, S., & Hassan, M. I. (2020) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2020.0105 · Cited by 23
Cardiovascular system and COVID-19: manifestations and therapeutics
Mahenthiran, A. K., Mahenthiran, A. K., & Mahenthiran, J. (2020) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm.2020.03.124 · Cited by 23
Cardiac electrophysiology consultative experience at the epicenter of the COVID-19 pandemic in the United States
Berman, J. P., Abrams, M. P., Kushnir, A., Rubin, G. A., EHLERT, F. A., BIVIANO, A. B., Morrow, J., Dizon, J. M., Wan, E. Y., Yarmohammadi, H., et al. (2020) · Indian Pacing and Electrophysiology Journal · doi:10.1016/j.ipej.2020.08.006 · Cited by 23
Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine
Peters, E. J. G., Collard, D., van Assen, S., Beudel, M., Bomers, M. K., Buijs, J., de Haan, L. R., de Ruijter, W., Douma, R. A., Elbers, P., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.10.004 · Cited by 23
Results of Open-Label non-Randomized Comparative Clinical Trial: “BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)
VIu, M., Orlova, Y. A., Геннадьевна, П. А., Павликова, Е. П., Мацкеплишвили, С. Т., Akopyan, Z. A., Seredenina, E. M., Potapenko, A. V., Агапов, М. А., Asratyan, D. A., et al. (2020) · Kardiologiia · doi:10.18087/cardio.2020.11.n1440 · Cited by 23
COVID ‐19 and the generation of novel scientific knowledge: Evidence‐based decisions and data sharing
Perillat, L., & Baigrie, B. S. (2021) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.13548 · Cited by 23
Chloroquine: Autophagy inhibitor, antimalarial, bitter taste receptor agonist in fight against COVID-19, a reality check?
Sharma, P. K., McAlinden, K. D., Ghavami, S., & Deshpande, D. A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173928 · Cited by 23
Learning to learn by yourself: Unsupervised meta‐learning with self‐knowledge distillation for COVID‐19 diagnosis from pneumonia cases
Zheng, W., Yan, L., Gou, C., Zhang, Z., Zhang, J. J., Hu, M., & Wang, F. (2021) · International Journal of Intelligent Systems · doi:10.1002/int.22449 · Cited by 23
Cardiovascular Safety of Hydroxychloroquine in US Veterans With Rheumatoid Arthritis
Faselis, C. J., Zeng‐Treitler, Q., Cheng, Y., Kerr, G. S., Nashel, D. J., Liappis, A. P., Weintrob, A., Karasik, P., Arundel, C., Boehm, D., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41803 · Cited by 23
Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update
Zhang, W., Qin, C., Fei, Y., Shen, M. Y., Zhou, Y., Zhang, Y., Zeng, X., & Zhang, S. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109022 · Cited by 23
Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?
Brest, P., Benzaquen, J., Klionsky, D. J., Hofman, P. M., & Mograbi, B. (2020) · Autophagy · doi:10.1080/15548627.2020.1779531 · Cited by 23
Prophylactic and Therapeutic Inhibition of In Vitro SARS-CoV-2 Replication by OleandrinPreprint
Plante, K. S., Plante, J. A., Fernandez, D. M., Mirchandani, D., Bopp, N. E., Aguilar, P. V., Sastry, K. J., Newman, R. A., & Weaver, S. C. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.15.203489 · Cited by 23
Update Alert 2: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19
Hernández, A. V., Roman, Y. M., Pasupuleti, V., Barboza, J. J., & White, C. M. (2020) · Annals of Internal Medicine · doi:10.7326/l20-1054 · Cited by 23
Prophylactic (hydroxy)chloroquine in COVID-19: Potential relevance for cardiac arrhythmia risk
Offerhaus, J. A., Wilde, A. A. M., & Remme, C. A. (2020) · Heart Rhythm · doi:10.1016/j.hrthm.2020.07.001 · Cited by 22
Antimalarials as Antivirals for COVID-19: Believe it or Not!
Saha, B. K., Bonnier, A., & Chong, W. H. (2020) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2020.08.019 · Cited by 22
Characterization of Critically Ill COVID-19 Patients at a Brooklyn Safety-Net Hospital
Capone, S., Abramyan, S., Ross, B., Rosenberg, J. R., Zeibeq, J., Vasudevan, V. P., Samad, R., Gerolemou, L. N., Pinelis, E., Gasperino, J., et al. (2020) · Cureus · doi:10.7759/cureus.9809 · Cited by 22
Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection
Giaime, P., Guenoun, M., Pedinielli, N., Narbonne, H., Bergounioux, J.-P., Solas, C., Guilhaumou, R., Sampol, J., Ollier, J., Sichez, H., et al. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa191 · Cited by 22
Available Compounds With Therapeutic Potential Against COVID-19: Antimicrobial Therapies, Supportive Care, and Probable Vaccines
Kumar, R., Srivastava, J. K., Singh, R., Siddiqui, M. H., Mansouri, R. A., Abdulhakim, J. A., Bin-Jumah, M. N., Alkahtani, S. H., Abdel‐Daim, M. M., & Uddin, M. S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.582025 · Cited by 22
Analyzing knowledge entities about COVID-19 using entitymetrics
Qi, Y., Wang, Q., Zhang, Y., Chen, C., Ryu, H., Park, N., Baek, J.-E., Li, K., Wu, Y., Li, D., et al. (2021) · Scientometrics · doi:10.1007/s11192-021-03933-y · Cited by 22
Mental health and quality of life for people with rheumatoid arthritis or ankylosing spondylitis in Aotearoa New Zealand following the COVID-19 national lockdown
Johnstone, G., Treharne, G. J., Fletcher, B. D., Lamar, R. S. M., White, D., Harrison, A. A., & Stebbings, S. M. (2021) · Rheumatology International · doi:10.1007/s00296-021-04952-x · Cited by 23
On the importance of physicochemical parameters of copper and aminosilane functionalized mesoporous silica for hydroxychloroquine release
Olejnik, A., & Gościańska, J. (2021) · Materials Science and Engineering C · doi:10.1016/j.msec.2021.112438 · Cited by 22
A Time-Series Feature-Based Recursive Classification Model to Optimize Treatment Strategies for Improving Outcomes and Resource Allocations of COVID-19 Patients
Wang, L., Yin, Z., Puppala, M., Ezeana, C. F., Wong, K., He, T., Gotur, D. B., & Wong, S. T. C. (2021) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2021.3139773 · Cited by 22
Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir
Moreno, S., Alcázar-Navarrete, B., Dueñas, C., del Castillo, J. G., Olalla, J., & Antela, A. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s356951 · Cited by 23
Demarcating Patriotic Science on Digital Platforms: Covid-19, Chloroquine and the Institutionalisation of Ignorance in Brazil
Fonseca, P. D. F. C., Ribeiro, B., & Nascimento, L. F. (2022) · Science as Culture · doi:10.1080/09505431.2022.2105691 · Cited by 22
Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study
Zhao, Q., Zheng, B., Han, B., Feng, P., Xia, Z., Jiang, H., Yin, Y., Zhu, J., Fei, C., Xiang, J., et al. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-023-00845-7 · Cited by 22
Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: authors' response
Fiolet, T., Guihur, A., Rebeaud, M. E., Mulot, M., Peiffer‐Smadja, N., & Mahamat‐Saleh, Y. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.10.002 · Cited by 22
COVID-19-Associated Hyper-Fibrinolysis: Mechanism and Implementations
Jacob, G., Aharon, A., & Brenner, B. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.596057 · Cited by 22
Hydroxychloroquine Does Not Increase the Risk of Cardiac Arrhythmia in Common Rheumatic Diseases: A Nationwide Population-Based Cohort Study
Lo, C.-H., Wei, J. C., Wang, Y., Tsai, C., Chan, K., Li, L.-C., Lo, T.-H., & Su, C.-H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.631869 · Cited by 22
Analysis and Forecasting Incidence, Intensive Care Unit Admissions, and Projected Mortality Attributable to COVID-19 in Portugal, the UK, Germany, Italy, and France: Predictions for 4 Weeks Ahead
Carvalho, K., Vicente, J. P., Jakovljević, M., & Teixeira, J. P. (2021) · Bioengineering · doi:10.3390/bioengineering8060084 · Cited by 22
It Takes Two to Tango: How the COVID-19 Vaccination Campaign in Israel Was Framed by the Health Ministry vs. the Television News
Gesser‐Edelsburg, A., Hijazi, R., & Cohen, R. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.887579 · Cited by 22
Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces
González-Gay, M. Á., Mayo, J., Castañeda, S., Martínez, J. M. C., & Hernández‐Rodríguez, J. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1770222 · Cited by 22
Treatment Response to Hydroxychloroquine, Lopinavir–Ritonavir, and Antibiotics for Moderate COVID-19: A First Report on the Pharmacological Outcomes from South KoreaPreprint
Kim, M. S., Jang, S.-W., Park, Y., Kim, B.-O., Hwang, T.-H., Kang, S. H., Kim, W. J., Kyu, P. S., Park, H.-W., Yang, W., et al. (2020) · medRxiv · doi:10.1101/2020.05.13.20094193 · Cited by 22
Retracted
Response to: ‘Correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine'' by Nikpour et al
Mathian, A., & Amoura, Z. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217875 · Cited by 22
Association between atherogenicity indices and prediabetes: a 5-year retrospective cohort study in a general Chinese physical examination population
Qiu, X., Han, Y. Y., Cao, C., Liao, Y., & Hu, H. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02768-8 · Cited by 21
A Comprehensive Updated Review on SARS‐CoV‐2 and COVID‐19
Ren, Y. R., Golding, A., Sorbello, A. F., Ji, P., Chen, J., Saluja, B., Witzmann, K. A., Arya, V., Reynolds, K. S., Choi, S., et al. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1673 · Cited by 21
Rheumatic Musculoskeletal Diseases and COVID-19 A Review of the First 6 Months of the Pandemic
Stradner, M. H., Dejaco, C., Zwerina, J., & Fritsch-Stork, R. D. E. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.562142 · Cited by 21
Cancer Patients with COVID-19: A Retrospective Study of 51 Patients in the District of Piacenza, Northern Italy
Cavanna, L., Citterio, C., Toscani, I., Franco, C., Magnacavallo, A., Caprioli, S., Cattadori, E., Nunzio, C. D., Pane, R., Schiavo, R., et al. (2020) · Future Science OA · doi:10.2144/fsoa-2020-0157 · Cited by 21
An Unusual Case of COVID-19 Presenting as Acute Psychosis
Lanier, C., Lewis, S. A., Patel, P. D., Ahmed, A. M., & Lewis, P. O. (2020) · Journal of Pharmacy Practice · doi:10.1177/0897190020977721 · Cited by 21
Obesity is a Major Risk Factor for Hospitalization in Community-Managed COVID-19 Pneumonia
Cottini, M., Lombardi, C., Berti, A., Gregis, M., Gregis, G., Bello, L., Mazid, M., Putignano, T., Corbellini, A., Belotti, S., et al. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.01.021 · Cited by 21
Clinical Effect of Traditional Chinese Medicine Shenhuang Granule in Critically Ill Patients with COVID-19: A Single-Centered, Retrospective, Observational Study
Feng, J., Fang, B., Zhou, D., Wang, J., Zou, D., Yu, G., Fen, Y., Peng, D., Hu, J., & Zhan, D. (2021) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2009.09029 · Cited by 21
COVID-19 treatment combinations and associations with mortality in a large multi-site healthcare system
Coppock, D., Baram, M., Chang, A. M., Henwood, P. C., Kubey, A. A., Summer, R. S., Zurlo, J. J., Li, M., & Hess, B. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252591 · Cited by 22
Effects of gravity and surface tension on steady microbubble propagation in asymmetric bifurcating airways
Munir, B., & Xu, Y. (2020) · Physics of Fluids · doi:10.1063/5.0012796 · Cited by 21
Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection
d’Ettorre, G., Recchia, G. E., Ridolfi, M., Siccardi, G., Pinacchio, C., Innocenti, G. P., Santinelli, L., Frasca, F., Bitossi, C., Ceccarelli, G., et al. (2020) · Medicine · doi:10.1097/md.0000000000021803 · Cited by 21

Authors: Geleris, J., Sun, Y., Platt, J., Zucker, J., Baldwin, M., Hripcsak, G., Labella, A., Manson, D. K., Kubin, C., Barr, R. G., Sobieszczyk, M. E., & Schluger, N. W.
Affiliations: Columbia University Irving Medical Center (US)
Corresponding author: Schluger, Neil W.
ORCID: Geleris, Joshua
Sun, Yifei
Platt, Jonathan
Zucker, Jason
Baldwin, Matthew
Hripcsak, George
Manson, Daniel K.
Kubin, Christine
Barr, R. Graham
Sobieszczyk, Magdalena E.
Schluger, Neil W.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2020-06-18
Volume: 382
Issue: 25
Pages: 2411-2418
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2012410
PMC: PMC7224609
OpenAlex: W3023346879
Cited by: 1,625
References: 17
Citations by year: 2026: 16 · 2025: 23 · 2024: 57 · 2023: 80 · 2022: 167 · 2021: 440 · 2020: 839
FWCI: 49.99
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (RO1-HL077612, RO1-HL093081, RO1-HL121270, RO1-LM006910)
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (200-2009-32593)
Topics: Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory Support and Mechanisms
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Keywords: hydroxychloroquine, COVID-19 pandemic, mechanical ventilation, intubation, mortality, hospitalized patients, antimalarial drugs, treatment efficacy, propensity score weighting, SARS-CoV-2
MeSH terms: Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Adult, Aged, Aged, 80 and over, Female, Hospitalization, Humans, Hydroxychloroquine, Intubation, Male, Middle Aged, New York City, Pneumonia, Viral, Treatment Failure, Coronavirus Infections, Propensity Score, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks